Hematologic Malignancy
Lymphoplasmacytic Lymphoma
CI-CAN-00007977Explore in graph →
Hematologic73 active trials2 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007977Explore in graph →
Clinical trials
347 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )(BAF_FRontier-1) | recruiting | Phase 1 | 215 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 22, 2026 |
| clinicaltrials |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03884998 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 | 85 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT06340737 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | recruiting | Phase 1 | 148 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 84 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 92 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01479842 | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 48 | Kami Maddocks, MDOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | not yet recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | recruiting | Phase 1 | 36 | C. Babis AndreadisOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | active not recruiting | Phase 1 / Phase 2 | 190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT01955499 | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT07249905 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | recruiting | Phase 1 / Phase 2 | 180 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03479268 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 248 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04775745 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | recruiting | Phase 1 | 60 | Newave Pharmaceutical IncINDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | recruiting | Phase 1 | 120 | Carna Biosciences, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07169565 | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia | not yet recruiting | Phase 1 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 11, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials